197 related articles for article (PubMed ID: 19643248)
1. Head and neck squamous cell carcinoma targeted chemosensitization.
Figures MR; Wobb J; Araki K; Liu T; Xu L; Zhu H; O'Malley BW; Li D
Otolaryngol Head Neck Surg; 2009 Aug; 141(2):177-83. PubMed ID: 19643248
[TBL] [Abstract][Full Text] [Related]
2. Molecular disruption of NBS1 with targeted gene delivery enhances chemosensitisation in head and neck cancer.
Araki K; Yamashita T; Reddy N; Wang H; Abuzeid WM; Khan K; O'Malley BW; Li D
Br J Cancer; 2010 Dec; 103(12):1822-30. PubMed ID: 21063405
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxicity and antiangiogenesis by fibroblast growth factor 2-targeted Ad-TK cancer gene therapy.
Saito K; Khan K; Sosnowski B; Li D; O'Malley BW
Laryngoscope; 2009 Apr; 119(4):665-74. PubMed ID: 19213040
[TBL] [Abstract][Full Text] [Related]
4. Molecular disruption of RAD50 sensitizes human tumor cells to cisplatin-based chemotherapy.
Abuzeid WM; Jiang X; Shi G; Wang H; Paulson D; Araki K; Jungreis D; Carney J; O'Malley BW; Li D
J Clin Invest; 2009 Jul; 119(7):1974-85. PubMed ID: 19487811
[TBL] [Abstract][Full Text] [Related]
5. E10A, an adenovirus-carrying endostatin gene, dramatically increased the tumor drug concentration of metronomic chemotherapy with low-dose cisplatin in a xenograft mouse model for head and neck squamous-cell carcinoma.
Adhim Z; Lin X; Huang W; Morishita N; Nakamura T; Yasui H; Otsuki N; Shigemura K; Fujisawa M; Nibu K; Shirakawa T
Cancer Gene Ther; 2012 Feb; 19(2):144-52. PubMed ID: 22116375
[TBL] [Abstract][Full Text] [Related]
6. Synergistic antitumor effect of AAV-mediated TRAIL expression combined with cisplatin on head and neck squamous cell carcinoma.
Jiang M; Liu Z; Xiang Y; Ma H; Liu S; Liu Y; Zheng D
BMC Cancer; 2011 Feb; 11():54. PubMed ID: 21291526
[TBL] [Abstract][Full Text] [Related]
7. Mutant Nbs1 enhances cisplatin-induced DNA damage and cytotoxicity in head and neck cancer.
Tran HM; Shi G; Li G; Carney JP; O'Malley B; Li D
Otolaryngol Head Neck Surg; 2004 Oct; 131(4):477-84. PubMed ID: 15467621
[TBL] [Abstract][Full Text] [Related]
8. The role of adenovirus-mediated retinoblastoma 94 in the treatment of head and neck cancer.
Li D; Day KV; Yu S; Shi G; Liu S; Guo M; Xu Y; Sreedharan S; O'Malley BW
Cancer Res; 2002 Aug; 62(16):4637-44. PubMed ID: 12183420
[TBL] [Abstract][Full Text] [Related]
9. Therapy of head and neck squamous cell carcinoma with replicative adenovirus expressing tissue inhibitor of metalloproteinase-2 and chemoradiation.
McNally LR; Rosenthal EL; Zhang W; Buchsbaum DJ
Cancer Gene Ther; 2009 Mar; 16(3):246-55. PubMed ID: 18846112
[TBL] [Abstract][Full Text] [Related]
10. Tumor reduction in vivo after adenoviral mediated gene transfer of the herpes simplex virus thymidine kinase gene and ganciclovir treatment in human head and neck squamous cell carcinoma.
Goebel EA; Davidson BL; Graham SM; Kern JA
Otolaryngol Head Neck Surg; 1998 Oct; 119(4):331-6. PubMed ID: 9781985
[TBL] [Abstract][Full Text] [Related]
11. A combined lymphokine-activated killer (LAK) cell immunotherapy and adenovirus-p53 gene therapy for head and neck squamous cell carcinoma.
Saito H; Ando S; Morishita N; Lee KM; Dator D; Dy D; Shigemura K; Adhim Z; Nibu K; Fujisawa M; Shirakawa T
Anticancer Res; 2014 Jul; 34(7):3365-70. PubMed ID: 24982341
[TBL] [Abstract][Full Text] [Related]
12. Insulin-like growth factor binding protein-3 suppresses vascular endothelial growth factor expression and tumor angiogenesis in head and neck squamous cell carcinoma.
Oh SH; Kim WY; Lee OH; Kang JH; Woo JK; Kim JH; Glisson B; Lee HY
Cancer Sci; 2012 Jul; 103(7):1259-66. PubMed ID: 22494072
[TBL] [Abstract][Full Text] [Related]
13. Interleukin 2 gene transfer prevents NKG2D suppression and enhances antitumor efficacy in combination with cisplatin for head and neck squamous cell cancer.
Li D; Ronson B; Guo M; Liu S; Bishop JS; Van Echo DA; O'Malley BW
Cancer Res; 2002 Jul; 62(14):4023-8. PubMed ID: 12124336
[TBL] [Abstract][Full Text] [Related]
14. Molecular disruption of the MRN(95) complex induces radiation sensitivity in head and neck cancer.
O'Malley BW; Li D; Carney J; Rhee J; Suntharalingam M
Laryngoscope; 2003 Sep; 113(9):1588-94. PubMed ID: 12972939
[TBL] [Abstract][Full Text] [Related]
15. Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma.
Chahlavi A; Todo T; Martuza RL; Rabkin SD
Neoplasia; 1999 Jun; 1(2):162-9. PubMed ID: 10933051
[TBL] [Abstract][Full Text] [Related]
16. Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck.
Liu TJ; el-Naggar AK; McDonnell TJ; Steck KD; Wang M; Taylor DL; Clayman GL
Cancer Res; 1995 Jul; 55(14):3117-22. PubMed ID: 7606733
[TBL] [Abstract][Full Text] [Related]
17. VE-822 Enhanced Cisplatin Chemotherapy Effects on Head and Neck Squamous Cell Carcinoma Drug-resistant Cells.
Chen T; Yang F; Dai X; Yu Y; Sun Y; Wu X; Li R; Zhou Q
Curr Cancer Drug Targets; 2023; 23(6):482-495. PubMed ID: 36748213
[TBL] [Abstract][Full Text] [Related]
18. S-Nitrosoglutathione-mediated STAT3 regulation in efficacy of radiotherapy and cisplatin therapy in head and neck squamous cell carcinoma.
Kaliyaperumal K; Sharma AK; McDonald DG; Dhindsa JS; Yount C; Singh AK; Won JS; Singh I
Redox Biol; 2015 Dec; 6():41-50. PubMed ID: 26177470
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of Cisplatin sensitivity in squamous cell carcinoma of the head and neck transfected with a survivin antisense gene.
Kojima H; Iida M; Yaguchi Y; Suzuki R; Hayashi N; Moriyama H; Manome Y
Arch Otolaryngol Head Neck Surg; 2006 Jun; 132(6):682-5. PubMed ID: 16785416
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 and MRN synergy in platinum-based chemoresistance of head and neck squamous cell carcinoma.
Shen B; Huang D; Ramsey AJ; Ig-Izevbekhai K; Zhang K; Lajud SA; O'Malley BW; Li D
Br J Cancer; 2020 Mar; 122(5):640-647. PubMed ID: 31853007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
